This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 03
  • /
  • NICE recommends Ajovy for prevention of migraine.-...

NICE recommends Ajovy for prevention of migraine.- Teva

Read time: 1 mins
Published:13th Mar 2020
The National Institute for Health and Care Excellence (NICE) has recommended Ajovy (fremanezumab), from Teva, in its Final Appraisal Document (FAD) for the prevention of migraine in adults with chronic migraine. NICE recommends Ajovy for chronic migraine patients who have not responded to at least three prior preventive drug treatments. Ajovy is one of several monoclonal antibodies specifically designed to target the CGRP (calcitonin gene-related peptide) pathway, a key contributor to migraine and is the first anti-CGRP preventive therapy approved by NICE. Ajovy is a long-acting treatment that offers monthly or quarterly dosing options and can be self-injected.
Condition: Migraine/Headache
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.